Arrowhead Research Corp. (ARWR) Trading 2.4% Higher
Arrowhead Research Corp. (NASDAQ:ARWR) shares traded up 2.4% during trading on Wednesday . The stock traded as high as $5.62 and last traded at $5.50, with a volume of 172,532 shares. The stock had previously closed at $5.37.
Several research analysts recently commented on the company. Chardan Capital assumed coverage on Arrowhead Research Corp. in a research note on Thursday, May 19th. They set a “buy” rating and a $12.00 target price for the company. Jefferies Group reissued a “hold” rating and set a $4.75 target price on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. Finally, Vetr raised Arrowhead Research Corp. from a “hold” rating to a “strong-buy” rating and set a $7.88 target price for the company in a research note on Wednesday, April 20th. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Arrowhead Research Corp. presently has a consensus rating of “Buy” and an average price target of $10.27.
The firm’s market capitalization is $334.58 million. The stock has a 50-day moving average of $5.73 and a 200-day moving average of $5.06.
Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.02. Equities analysts predict that Arrowhead Research Corp. will post ($1.40) earnings per share for the current year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.